Growth Metrics

Volitionrx (VNRX) Cash from Financing Activities (2019 - 2025)

Volitionrx filings provide 9 years of Cash from Financing Activities readings, the most recent being $6.2 million for Q4 2025.

  • On a quarterly basis, Cash from Financing Activities rose 168.83% to $6.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $17.1 million, a 97.44% increase, with the full-year FY2025 number at $17.1 million, up 97.44% from a year prior.
  • Cash from Financing Activities hit $6.2 million in Q4 2025 for Volitionrx, up from $1.6 million in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $20.2 million in Q1 2021 to a low of -$460198.0 in Q2 2022.
  • Median Cash from Financing Activities over the past 5 years was $2.2 million (2021), compared with a mean of $4.2 million.
  • The widest YoY moves for Cash from Financing Activities: up 13203.23% in 2022, down 191.81% in 2022.
  • Volitionrx's Cash from Financing Activities stood at $2.1 million in 2021, then tumbled by 55.85% to $925964.0 in 2022, then soared by 307.19% to $3.8 million in 2023, then tumbled by 39.27% to $2.3 million in 2024, then skyrocketed by 168.83% to $6.2 million in 2025.
  • The last three reported values for Cash from Financing Activities were $6.2 million (Q4 2025), $1.6 million (Q3 2025), and $5.7 million (Q2 2025) per Business Quant data.